Product Dossier
AVAMYS
Product Dossier for AVAMYS (fluticasone furoate, GlaxoSmithKline). ARTG record, PBS listing, PBAC outcomes — compiled by arcimedes.
- Sponsor: GlaxoSmithKline
- Active ingredient: fluticasone furoate
- Therapeutic area: Respiratory
- Related brand: Arnuity Ellipta
- Related brand: TRELEGY ELLIPTA
- Related brand: Breo Ellipta
- Same area: NUCALA
- Same area: VENTOLIN
I cannot write a
Brand Dossier for AVAMYS based on the provided source documents.
The documents supplied describe TRELEGY ELLIPTA (fluticasone furoate/umeclidinium/vilanterol), which is a different medicine from AVAMYS. AVAMYS is a fluticasone furoate nasal spray for nasal indications, whereas TRELEGY ELLIPTA is an inhaled powder for asthma and COPD.
The only information provided about AVAMYS itself is: — ARTG registration 131443 (nasal spray, first listed 2008-02-14) — PBAC outcomes from 2017 relating to COPD (not recommended)
The comprehensive clinical and safety data in the first document pertains to TRELEGY ELLIPTA, not AVAMYS, and would be inappropriate to cite for an AVAMYS dossier.
To prepare an accurate Brand Dossier for AVAMYS nasal spray, I would need source documents that specifically describe the AVAMYS product, including its approved indications, dosing, safety profile, and regulatory history for nasal use.